GNMX - Aevi Genomic Medicine, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.936
+0.021 (+2.30%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.915
Open0.930
Bid0.830 x 1000
Ask1.200 x 18000
Day's Range0.920 - 0.960
52 Week Range0.830 - 2.650
Volume33,304
Avg. Volume109,847
Market Cap55.54M
Beta1.95
PE Ratio (TTM)N/A
EPS (TTM)-0.688
Earnings DateMay 8, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.58
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    Aevi Genomic Medicine, Inc. Announces Novel Co-crystal Version of AEVI-001

    -FDA provisionally agreed that AEVI-004 is a co-crystal and a novel drug substance -FDA provisionally agreed existing AEVI-001 toxicology and pathology studies are acceptable to support clinical development ...

  • Zacks Small Cap Researchlast month

    GNMX: ASCEND Will Enroll To N=64, (consistent with initial trial design)

    Indicating that after an interim look at the placebo arm, the decision was made to continue to enroll to n=64 in order to “ensure sufficient power to detect a robust treatment effect”. In other words, in order to further reduce the risk of placebo effect. Importantly, this decision was based solely on a statistically-derived estimate of placebo response based solely on the placebo arm (i.e.

  • PR Newswirelast month

    Aevi Genomic Medicine to Present at the The 2018 JMP Securities Life Sciences Conference

    PHILADELPHIA , June 13, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the ...

  • Aevi Genomic Medicine Provides Update on Sample Size Re-estimation for Phase 2 ASCEND Trial in ADHD
    PR Newswirelast month

    Aevi Genomic Medicine Provides Update on Sample Size Re-estimation for Phase 2 ASCEND Trial in ADHD

    The decision to increase the sample size was made according to the protocol defined sample size re-estimatation design, which allows an adjustment in the sample size after an interim analysis of the placebo arm to ensure the trial is appropriately powered.  As a result of the interim analysis performed by an independent unblinded statistician, the sample size will be increased from 42 to 64 patients.

  • Zacks Small Cap Research2 months ago

    GNMX: Development Timelines Intact, Including AEVI-001 Ph2 ADHD Data Expected ~Mid-Year

    By Brian Marckx, CFA NASDAQ:GNMX READ THE FULL RESEARCH REPORT Q1 2018 Results / Operational Update : Pipeline Development Timelines Tracking Prior Expectations… Aevi Genomic Medicine (NASDAQ:GNMX) reported ...

  • GlobeNewswire2 months ago

    Consolidated Research: 2018 Summary Expectations for CorVel, Consol Energy, Ardelyx, Aevi Genomic Medicine, Proofpoint, and Brink's — Fundamental Analysis, Key Performance Indications

    NEW YORK, May 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CorVel ...

  • PR Newswire2 months ago

    Aevi Genomic Medicine to Present at the Jefferies 2018 Global Healthcare Conference

    PHILADELPHIA , May 29, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the Jefferies ...

  • ACCESSWIRE2 months ago

    Wired News - uniQure Announced Presentation of Preclinical Data Demonstrating Advances in Distribution of Gene Therapy at ASGCT Annual Meeting in Chicago

    LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on uniQure N.V. (NASDAQ: QURE), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=QURE as the Company's latest news hit the wire. On May 18, 2018, the Company announced that it has reported preclinical data in three poster presentations highlighting its expertise in efficient transduction of target cells within affected organs at American Society of Gene and Cell Therapy (ASGCT) 21st Annual Meeting held in Chicago, Illinois, May 17-18, 2018. The presentations highlighted that uniQure's modular platform is now broadly applicable to treat patients with both liver and central nervous system (CNS) disorders.

  • Associated Press2 months ago

    Aevi Genomic Medicine: 1Q Earnings Snapshot

    The Wayne, Pennsylvania-based company said it had a loss of 15 cents per share. The company's shares closed at $1.51. A year ago, they were trading at $1.40. _____ This story was generated by Automated ...

  • PR Newswire2 months ago

    Aevi Genomic Medicine Reports First Quarter 2018 Financial Results and Provides Business Update

    PHILADELPHIA , May 15, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") announced today financial and operational results for the three months ended March 31 , ...

  • What Are Analysts Expecting From Aevi Genomic Medicine Inc (NASDAQ:GNMX) Over The Next Few Years?
    Simply Wall St.2 months ago

    What Are Analysts Expecting From Aevi Genomic Medicine Inc (NASDAQ:GNMX) Over The Next Few Years?

    Aevi Genomic Medicine Inc’s (NASDAQ:GNMX) latest earnings update in December 2017 signalled that losses became smaller relative to the prrior year’s level as a result of recent tailwinds Below, I’veRead More...

  • Business Wire3 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Aevi Genomic Medicine, Inc. -- GNMX

    Levi & Korsinsky announces it has commenced an investigation of Aevi Genomic Medicine, Inc. concerning possible breaches of fiduciary duty. To obtain additiona

  • PR Newswire3 months ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Aevi Genomic Medicine, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , April 29, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • Zacks Small Cap Research4 months ago

    GNMX: ASCEND Timeline On-Track, Topline ~Mid-2018. Additional Pipeline Expansion

    By Brian Marckx, CFA NASDAQ:GNMX Aevi (NASDAQ:GNMX) reported financial results for their fourth quarter on March 13th.  The operational update covered the two AEVI-001 programs (ADHD and ASD), AEVI-002 ...

  • Zacks Small Cap Research4 months ago

    GNMX: Q4 2017 Results / Operational Update

    By Brian Marckx, CFA NASDAQ:GNMX Aevi (NASDAQ:GNMX) reported financial results for their fourth quarter on March 13th.  The operational update covered the two AEVI-001 programs (ADHD and ASD), AEVI-002 ...

  • PR Newswire4 months ago

    Aevi Genomic Medicine to Present at the 17th Annual Needham Healthcare Conference

    PHILADELPHIA, March 20, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present at the 17th Annual Needham Healthcare Conference at 8:30 AM EDT on Wednesday, March 28, 2018 at the Westin Grand Central Hotel, New York. Aevi Genomic Medicine, Inc. is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies.

  • PR Newswire4 months ago

    Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

    PHILADELPHIA , March 13, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today financial and operational results for the three and twelve months ended December ...

  • ACCESSWIRE4 months ago

    Aevi Genomic Medicine, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Aevi Genomic Medicine, Inc. (NASDAQ: GNMX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 13, 2018, at 8:30 AM Eastern ...

  • American City Business Journals5 months ago

    Aevi expands drug development deal with Japanese biopharm firm

    Aevi Genomic Medicine said Wednesday it has expanded its collaboration with a Japanese biopharmaceutical company. Under the expanded partnership, Aevi of Wayne, Pa., signed an an option agreement for Kyowa Hakko Kirin Co. Ltd.'s early stage monoclonal antibody program in an ultra-orphan pediatric indication. Both the rare disease being targeted and the financial terms of the expanded deal are being kept confidential.

  • PR Newswire5 months ago

    Aevi Genomic Medicine Expands Collaboration with Kyowa Hakko Kirin

    PHILADELPHIA, March 7, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ MKT: GNMX) today announced that it has expanded its collaboration with Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) with the signing of an option agreement for an early stage monoclonal antibody program ("program") in an ultra-orphan pediatric indication. Aevi Genomic Medicine and Kyowa Hakko Kirin have developed a collaboration framework to advance preclinical programs into the clinic, leveraging Aevi Genomic Medicine's expertise in rare and orphan pediatric diseases, and its ongoing collaboration with Children's Hospital of Philadelphia ("CHOP") and the biobank at the Center for Applied Genomics at CHOP.

  • PR Newswire5 months ago

    Aevi Genomic Medicine to Host Conference Call to Announce Fourth Quarter and Year End 2017 Financial Results

    PHILADELPHIA , March 6, 2017 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today it will host a conference call and live audio webcast on Tuesday, March 13, 2018 at 8:30 ...

  • PR Newswire8 months ago

    Aevi Genomic Medicine Announces New Appointment to its Board of Directors

    PHILADELPHIA, Dec. 4, 2017 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) (the Company) announced today the appointment of Matthew D. Bayley, MD, MBA to its Board of Directors. "We are excited to welcome Matt to our Board of Directors during this important time for the Company," said Mike Cola, CEO of Aevi Genomic Medicine. Dr. Bayley currently serves as a Senior Vice President and Chief Strategy Officer at the Children's Hospital of Philadelphia (CHOP) where he leads strategic planning and business development efforts and supports the CEO in developing the strategy of advancing CHOP's mission.  Prior to joining CHOP, he was a Partner at McKinsey & Company, a global management consulting firm, where his work focused on strategy, operations, and organizational topics in the healthcare field.  Dr. Bayley graduated from the University of Virginia's McIntire School of Commerce, and went on to receive his M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from the Wharton School.

  • Zacks Small Cap Research8 months ago

    GNMX: Still Expect ADHD Data Mid-2018, Could Be Next Value-Inflection Point

    Aevi (GNMX) reported financial results for their third quarter on November 2nd.  The operational update mostly relates to timelines of the various ongoing studies – while this includes an anticipated slight delay to the anti-LIGHT signal finding study in pediatric onset Crohn’s, it appears status of the two AEVI-001 programs (ADHD and ASD) remain largely inline with earlier expectations. Cash used in operating activities was $6.4M and $24.9M ($7.7M and $24.8M, ex-changes in working capital) in Q3 and the first nine months of 2017, respectively.  Cash balance at quarter-end was $15.0M but pro-forma for net proceeds from the equity sale in October (details below), cash balance was approximately $42M - which represents ~17 months (5 – 6 quarters) of operating capital at the current burn rate.  The company expects current cash to be sufficient to fund operations into 2019 – by that time they should have announced initial data from AEVI-001 phase II in ADHD and, possibly from AEVI-001 in pediatric onset Crohn’s (i.e.